| Also known as |
Botox, onabotulinumtoxinA |
| Blood pressure |
No significant effect |
| Chemical name |
Botulinum toxin type A |
| Dosage (medical) |
20-100 units injected intramuscularly, depending on treatment area |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces muscle activity, treats wrinkles, muscle spasms, and excessive sweating |
| Formula |
C6760H10447N1743O2010S32 |
| Half-life |
2-6 months |
| Hepatotoxicity |
No known hepatotoxic effects |
| Lab Test |
Mouse bioassay for potency testing |
| Main action |
Blocks the release of acetylcholine at neuromuscular junctions |
| Raw Material |
BOTILIMUS TOXINE |
| Side effects |
Pain at injection site, headache, muscle weakness, drooping eyelids, dysphagia, spread of toxin effects |
| Storage conditions |
Refrigerated, 2-8В°C |
| Substance class |
Neurotoxin |
| Trade name |
Botox, Dysport, Xeomin |
| Use in sports |
None, usage in sports would be considered misuse |
| Water Retention |
No significant effect |
| Manufacturer |
Pharma Grade |
| Packing |
BOTOX 100 UNITS |
